EA201692422A1 - Состав, содержащий пролекарство гемцитабина - Google Patents

Состав, содержащий пролекарство гемцитабина

Info

Publication number
EA201692422A1
EA201692422A1 EA201692422A EA201692422A EA201692422A1 EA 201692422 A1 EA201692422 A1 EA 201692422A1 EA 201692422 A EA201692422 A EA 201692422A EA 201692422 A EA201692422 A EA 201692422A EA 201692422 A1 EA201692422 A1 EA 201692422A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gemcitabine
relates
hemcitabin
preservation
composition containing
Prior art date
Application number
EA201692422A
Other languages
English (en)
Other versions
EA033046B1 (ru
Inventor
Хью Гриффит
Гордон Кенновин
Original Assignee
Нукана Байомед Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Priority claimed from GBGB1417646.5A external-priority patent/GB201417646D0/en
Application filed by Нукана Байомед Лимитед filed Critical Нукана Байомед Лимитед
Publication of EA201692422A1 publication Critical patent/EA201692422A1/ru
Publication of EA033046B1 publication Critical patent/EA033046B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим составам гемцитабин-[фенилбензокси-L-аланинил)]фосфата, монофосфатного производного хорошо известного противоопухолевого лекарственного средства гемцитабина. В частности, изобретение относится к составам, которые содержат полярный апротонный растворитель, предпочтительно диметилацетамид (ДМА). Составы, содержащие указанный растворитель, оказывают терапевтически эффективное лечение гемцитабин-[фенилбензокси-L-аланинил)]фосфатом. Изобретение также относится к способам применения указанных составов и наборов, содержащих указанные составы.
EA201692422A 2014-06-25 2015-06-25 Состав, содержащий пролекарство гемцитабина EA033046B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2050MU2014 2014-06-25
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
GBGB1417646.5A GB201417646D0 (en) 2014-10-06 2014-10-06 Formulations of phosphate derivatives
PCT/GB2015/051858 WO2015198059A1 (en) 2014-06-25 2015-06-25 Formulation comprising a gemcitabine-prodrug

Publications (2)

Publication Number Publication Date
EA201692422A1 true EA201692422A1 (ru) 2017-04-28
EA033046B1 EA033046B1 (ru) 2019-08-30

Family

ID=53499028

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692422A EA033046B1 (ru) 2014-06-25 2015-06-25 Состав, содержащий пролекарство гемцитабина

Country Status (29)

Country Link
US (4) US10117888B2 (ru)
EP (2) EP3269391A1 (ru)
JP (3) JP6855248B2 (ru)
KR (2) KR20220104270A (ru)
CN (2) CN106470672B (ru)
AU (2) AU2015278900B2 (ru)
BR (1) BR112016025787B1 (ru)
CA (1) CA2944966C (ru)
CL (1) CL2016003261A1 (ru)
CY (1) CY1119772T1 (ru)
DK (1) DK3119794T3 (ru)
EA (1) EA033046B1 (ru)
ES (1) ES2655820T3 (ru)
HK (1) HK1244437A1 (ru)
HR (1) HRP20180007T1 (ru)
HU (1) HUE036011T2 (ru)
IL (2) IL248345B (ru)
LT (1) LT3119794T (ru)
MX (2) MX2020004054A (ru)
MY (1) MY186584A (ru)
NO (1) NO3119794T3 (ru)
PH (1) PH12016502552A1 (ru)
PL (1) PL3119794T3 (ru)
PT (1) PT3119794T (ru)
RS (1) RS56752B1 (ru)
SG (1) SG11201608809RA (ru)
SI (1) SI3119794T1 (ru)
TW (2) TWI765176B (ru)
WO (1) WO2015198059A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2012117246A1 (en) 2011-03-01 2012-09-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
SI3235824T1 (sl) 2012-11-16 2019-08-30 University College Cardiff Consultants Limited Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
RS60968B1 (sr) * 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
MX2020004054A (es) 2014-06-25 2021-11-30 NuCana plc Formulacion que comprende un profarmaco de gemcitabina.
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
DK3224268T3 (da) 2014-11-28 2019-09-02 NuCana plc Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser
CN112156102B (zh) 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
US10660912B2 (en) 2015-10-05 2020-05-26 NuCana plc Combination therapy for cancer
MY196772A (en) 2015-12-11 2023-05-03 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
EP3534961A4 (en) 2016-11-02 2020-05-27 Centrexion Therapeutics Corporation STABLE AQUEOUS INJECTABLE CAPSAICIN FORMULATIONS AND MEDICAL USES THEREOF
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN111201015A (zh) 2017-07-20 2020-05-26 中枢疗法公司 使用辣椒素治疗疼痛的方法和组合物
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN109956986B (zh) 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
WO2023076878A1 (en) * 2021-10-26 2023-05-04 Emphascience Inc. Ready-to-dilute formulation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DK1045897T3 (da) 1998-01-23 2002-05-13 Newbiotics Inc Enzymatisk katalyserede, terapeutiske midler
JP4982019B2 (ja) 1999-07-22 2012-07-25 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド 酵素によって触媒される治療活性化
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1845787B1 (en) * 2005-01-27 2015-04-15 Erimos Pharmaceuticals LLC Formulations for injection of catecholic butanes, including ndga compounds, into animals
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
WO2011008985A2 (en) * 2009-07-15 2011-01-20 Georgia Tech Research Corporation Methods and compositions for improved delivery of therapeutic and diagnostic agents
WO2011062503A1 (en) * 2009-11-20 2011-05-26 Clavis Pharma As Parenteral formulations of gemcitabine derivatives
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR101231925B1 (ko) * 2010-10-27 2013-02-08 씨제이제일제당 (주) 젬시타빈의 전구약물 및 이의 제조방법
JP5933033B2 (ja) * 2012-01-20 2016-06-08 アラタナ セラピューティクス エン ヴェー 点眼剤組成物
CN104955458A (zh) * 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
SI3235824T1 (sl) 2012-11-16 2019-08-30 University College Cardiff Consultants Limited Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
MX2020004054A (es) 2014-06-25 2021-11-30 NuCana plc Formulacion que comprende un profarmaco de gemcitabina.
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
KR20180021697A (ko) 2015-05-14 2018-03-05 뉴카나 피엘씨 암 치료
US10660912B2 (en) 2015-10-05 2020-05-26 NuCana plc Combination therapy for cancer
MY196772A (en) 2015-12-11 2023-05-03 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
US20190381084A1 (en) 2015-12-23 2019-12-19 Nucana Biomed Limited Combination therapy
MD3393478T2 (ro) 2015-12-23 2020-04-30 NuCana plc Terapie combinată
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
CN106470672A (zh) 2017-03-01
AU2019204557A1 (en) 2019-07-18
US11040051B2 (en) 2021-06-22
BR112016025787A2 (pt) 2017-08-15
NZ725009A (en) 2021-02-26
PT3119794T (pt) 2018-01-15
CN110882268A (zh) 2020-03-17
JP2017519022A (ja) 2017-07-13
RS56752B1 (sr) 2018-04-30
TW201945007A (zh) 2019-12-01
EA033046B1 (ru) 2019-08-30
KR102421929B1 (ko) 2022-07-15
JP2022031659A (ja) 2022-02-22
US20170095498A1 (en) 2017-04-06
DK3119794T3 (en) 2018-01-22
MX2016015629A (es) 2017-08-02
HRP20180007T1 (hr) 2018-02-23
IL276199B (en) 2022-04-01
US10117888B2 (en) 2018-11-06
US20190022118A1 (en) 2019-01-24
CL2016003261A1 (es) 2017-10-06
NO3119794T3 (ru) 2018-03-10
BR112016025787B1 (pt) 2022-12-13
CY1119772T1 (el) 2018-06-27
IL276199A (en) 2020-09-30
US20220031727A1 (en) 2022-02-03
TW201613611A (en) 2016-04-16
HK1244437A1 (zh) 2018-08-10
CA2944966C (en) 2022-10-25
TWI674097B (zh) 2019-10-11
MX2020004054A (es) 2021-11-30
SI3119794T1 (en) 2018-02-28
AU2015278900B2 (en) 2019-04-04
EP3119794B1 (en) 2017-10-11
JP6855248B2 (ja) 2021-04-07
CN106470672B (zh) 2019-11-05
CA2944966A1 (en) 2015-12-30
JP2020079255A (ja) 2020-05-28
IL248345B (en) 2020-10-29
TWI765176B (zh) 2022-05-21
US20200397810A1 (en) 2020-12-24
KR20170042501A (ko) 2017-04-19
AU2015278900A1 (en) 2016-10-27
JP7329025B2 (ja) 2023-08-17
JP6970221B2 (ja) 2021-11-24
SG11201608809RA (en) 2016-11-29
KR20220104270A (ko) 2022-07-26
WO2015198059A1 (en) 2015-12-30
EP3119794A1 (en) 2017-01-25
PH12016502552A1 (en) 2017-04-10
LT3119794T (lt) 2018-02-12
IL248345A0 (en) 2016-11-30
PL3119794T3 (pl) 2018-04-30
AU2019204557B2 (en) 2020-08-27
ES2655820T3 (es) 2018-02-21
EP3269391A1 (en) 2018-01-17
US10786523B2 (en) 2020-09-29
US11707477B2 (en) 2023-07-25
HUE036011T2 (hu) 2018-06-28
MY186584A (en) 2021-07-28

Similar Documents

Publication Publication Date Title
EA201692422A1 (ru) Состав, содержащий пролекарство гемцитабина
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692060A1 (ru) Активаторы ионного канала и способы их применения
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA202090547A2 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201791733A1 (ru) Производные 9h-пирролодипиридина
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA201790570A1 (ru) Модуляторы р2х7
EA202190058A1 (ru) Композиции фосфорамидатных производных нуклеозидных лекарственных средств
EA201890572A1 (ru) Биофармацевтические композиции
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2020004454A (es) Manufactura de productos de interpolimero de etileno a una mayor tasa de produccion.
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение